ABCAM Plc Notice of Results (9558H)
August 24 2016 - 2:01AM
UK Regulatory
TIDMABC
RNS Number : 9558H
ABCAM Plc
24 August 2016
24 August 2016
ABCAM PLC
("Abcam" or "the Company")
Notice of Preliminary Results
Cambridge UK: Abcam plc (AIM: ABC), a global leader in the
supply of life science research tools, will announce its
preliminary results for the year ended 30 June 2016 on 12 September
2016. A briefing for analysts will be held at 09.30 BST on 12
September at the offices of FTI Consulting, 200 Aldersgate,
Aldersgate Street, London, EC1A 4HD. A live audio webcast and slide
presentation of this event will also be available at
www.abcamplc.com.
##Ends##
For further information, please contact:
+ 44 (0) 1223
Abcam 696 000
Alan Hirzel, Chief Executive
Officer
Jeff Iliffe, Chief Financial
Officer
Julia Wilson - Investor Relations
J.P.Morgan Cazenove - Nominated + 44 (0) 20 7742
Advisor & Corporate Broker 4000
James Mitford / Christopher Cargill
+ 44 (0) 20 3727
FTI Consulting 1000
Ben Atwell / Brett Pollard /
Natalie Garland-Collins
Notes for editors:
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's ten offices are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
Forward looking statement
This announcement, including any information included or
incorporated by reference in this announcement, may contain
forward-looking statements (including words such as "believe",
"expect", "estimate", "intend", "anticipate" and words of similar
meaning) which are based upon current expectations and assumptions
regarding anticipated developments and other factors affecting the
Abcam Group. All statements other than statements of historical
facts may be forward-looking statements and should not be treated
as guarantees of future performance. These forward-looking
statements involve risks and uncertainties, many of which are
beyond the control of the Abcam Group, and there are important
factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements.
These forward-looking statements speak only as at the date of this
announcement and accordingly undue reliance should not be placed on
such statements. The Abcam Group does not assume any obligation to,
and does not intend to, revise or update these forward-looking
statements, except as required pursuant to applicable law.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBRGDIDBDBGLX
(END) Dow Jones Newswires
August 24, 2016 02:01 ET (06:01 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024